Business Description
Serina Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US81751A1088
Description
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | -0.4 | |||||
| Debt-to-Equity | -2.57 | |||||
| Debt-to-EBITDA | -1.67 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.76 | |||||
| 9-Day RSI | 35.35 | |||||
| 14-Day RSI | 38.6 | |||||
| 3-1 Month Momentum % | -22.36 | |||||
| 6-1 Month Momentum % | -48.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.64 | |||||
| Quick Ratio | 0.64 | |||||
| Cash Ratio | 0.62 | |||||
| Days Sales Outstanding | 0.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -454 | |||||
| Net Margin % | -536.4 | |||||
| FCF Margin % | -2513 | |||||
| ROA % | -67.7 | |||||
| ROIC % | -40.39 | |||||
| ROC (Joel Greenblatt) % | -581.71 | |||||
| ROCE % | -281.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.95 | |||||
| PS Ratio | 71.21 | |||||
| EV-to-EBIT | -7.85 | |||||
| EV-to-EBITDA | -7.92 | |||||
| EV-to-Revenue | 104.85 | |||||
| EV-to-FCF | -15.07 | |||||
| Earnings Yield (Greenblatt) % | -12.74 | |||||
| FCF Yield % | -7.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:SER
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Serina Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.5 | ||
| EPS (TTM) ($) | -2.74 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 38.6 | ||
| 14-Day ATR ($) | 0.619226 | ||
| 20-Day SMA ($) | 5.055255 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 3.81 - 19.93 | ||
| Shares Outstanding (Mil) | 9.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Serina Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Serina Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Serina Therapeutics Inc Frequently Asked Questions
What is Serina Therapeutics Inc(SER)'s stock price today?
The current price of SER is $4.51. The 52 week high of SER is $19.93 and 52 week low is $3.81.
When is next earnings date of Serina Therapeutics Inc(SER)?
The next earnings date of Serina Therapeutics Inc(SER) is 2025-02-28 Est..
Does Serina Therapeutics Inc(SER) pay dividends? If so, how much?
Serina Therapeutics Inc(SER) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers